Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This adeno-associated virus (AAV) vector is a gene therapy construct designed to express the human angiotensinogen (AGT) protein. Angiotensinogen is the sole substrate for the renin-angiotensin system (RAS), where its cleavage by renin is the rate-limiting step in the production of angiotensin peptides. In preclinical research, specifically in LDL receptor-deficient mouse models, this vector is used to investigate the functional roles of AGT domains in blood pressure regulation and the development of atherosclerosis. The construct allows for the study of species-specific renin-AGT interactions and the potential AngII-independent functions of AGT, such as its interaction with megalin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adeno-associated virus encoding human angiotensinogen.